A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 2077-2080

  Smith, Robert A ^a   Klarmann, George J ^a   Stray, Kirsten M ^a   Von Schwedler, Uta K ^a   Schinazi, Raymond F ^b   Preston, Bradley D ^a   North, Thomas W ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL;

EID: 0032817243     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.2077     Document Type: Article

References (46)

1. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
2. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
3. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
4. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV 1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241:651-662.
5. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. Cronn, R. C., K. M. Remington, B. D. Preston, and T. W. North. 1992. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′-deoxyadenosine-5′-triphosphate. Biochem. Pharmacol. 44:1375-1381.
7. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann. Intern. Med. 122:401-408.
8. Doolittle, R. F., D. F. Feng, M. S. Johnson, and M. A. McClure. 1989. Origins and evolutionary relationships of retroviruses. Q. Rev. Biol. 64:1-30.
9. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
10. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV 1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
11. Im, G. J., E. Tramontano, C. J. Gonzalez, and Y. C. Cheng. 1993. Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance. Biochem. Pharmacol. 46:2307-2313.
12. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
13. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
14. Kemp, S. D., C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J. Virol. 72:5093-5098.
15. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
16. Korber, B., B. Hahn, B. Foley, J. W. Mellors, T. Leitner, G. Myers, F. McCutchan, and F. Kuiken (ed.). December 1998, revision date. Human retroviruses and AIDS 1998: a compilation and analysis of nucleic acid and amino acid sequences. [Online.] Theoretical Biology and Biophysics Group, Los Alamos, N. Mex. http://hiv-web.lanl.gov. [11 March 1999, last date accessed.]
17. Kuritzkes, D. R., J. B. Quinn, S. L. Benoit, D. L. Shugarts, A. Griffin, M. Bakhtiari, D. Poticha, J. J. Eron, M. A. Fallon, and M. Rubin. 1996. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
18. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267: 15789-15794.
19. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
20. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
21. Mellors, J. W., H. Z. Bazmi, R. F. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Weir, and D. L. Mayers. 1995. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
22. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
23. Miller, V., A. Phillips, C. Rottmann, S. Staszewski, R. Pauwels, K. Hertogs, M. P. de Bethune, S. D. Kemp, S. Bloor, P. R. Harrigan, and B. A. Larder. 1998. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J. Infect. Dis. 177:1521-1532.
24. Miller, V., M. Sturmer, S. Staszewski, B. Groschel, K. Hertogs, M. P. de Bethune, R. Pauwels, P. R. Harrigan, S. Bloor, S. D. Kemp, and B. A. Larder. 1998. The M184V mutation in HIV 1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross resistance to nucleoside analogue RT inhibitors. AIDS 12:705-712.
25. Nijhuis, M., R. Schuurman, D. de Jong, R. van Leeuwen, J. Lange, S. Danner, W. Keulen, T. de Groot, and C. A. Boucher. 1997. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J. Infect. Dis. 176:398-405.
26. North, T. W., R. C. Cronn, K. M. Remington, and R. T. Tandberg. 1990. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob. Agents Chemother. 34:1505-1507.
27. O'Neil, P. K., G. Sun, H. Yu, J. P. Dougherty, and B. D. Preston. Unpublished results.
28. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high titer helper free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
29. Prasad, V. R., I. Lowy, T. de los Santos, L. Chiang, and S. P. Goff. 1991. Isolation and characterization of a dideoxyguanosine triphosphate resistant mutant of human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 88:11363-11367.
30. Preston, B. D. 1997. Reverse transcriptase fidelity and HIV 1 variation. Science 275:228-229.
31. Remington, K. M., Y.-Q. Zhu, T. R. Phillips, and T. W. North. 1994. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J. Virol. 68:632-637.
32. Richman, D. D. 1994. Resistance, drug failure, and disease progression. AIDS Res. Hum. Retroviruses 10:901-905.
33. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1999. Resistance table: mutations in retroviral genes associated with drug resistance. 1999-2000 update. Int. Antivir. News 7:46-69.
34. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
35. Smith, R. A., K. M. Remington, B. D. Preston, R. F. Schinazi, and T. W. North. 1998. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-β-2′,3′-dideoxy-3′-thiacytidine and 3′-azido-3′-deoxythymidine. J. Virol. 72:2335-2340.
36. Stahlhut, M. W., and D. B. Olsen. 1996. Expression and purification of retroviral HIV 1 reverse transcriptase. Methods Enzymol. 275:122-133.
37. Swingler, S., P. Gallay, D. Camaur, J. Song, A. Abo, and D. Trono. 1997. The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J. Virol. 71:4372-4377.
38. Tachedjian, G., D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, and J. Mills. 1995. Characterisation of foscarnet resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
39. Tachedjian, G., J. Mellors, H. Bazmi, C. Birch, and J. Mills. 1996. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol. 70:7171-7181.
40. Tachedjian, G., J. W. Mellors, H. Bazmi, and J. Mills. 1998. Impaired fitness of foscarnet resistant strains of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:1059-1064.
41. Tian, H., J. Whitcomb, K. Limoli, T. Wrin, G. Winslow, N. Parkin, D. Smith, Y. Lie, M. Bakthiari, D. Shugarts, R. Schooley, D. Kuritzkes, and C. Petropoulos. 1998. Zidovudine/lamivudine co-resistance is preceded by a transient period of zidovudine hypersensitivity, abstr. 30, p. 22-23. In Programme and abstracts of the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. International Medical Press, London, United Kingdom.
42. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
43. Tramontano, E., G. Piras, J. W. Mellors, M. Putzolu, H. Z. Bazmi, and P. La Colla. 1998. Biochemical characterization of HIV 1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate. Biochem. Pharmacol. 56:1583-1589.
44. Wainberg, M. A., M. D. Miller, Y. Quan, H. Solomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther., in press.
45. Wilson, J. E., A. Aulabaugh, B. Caligan, S. McPherson, J. K. Wakefield, S. Jablonski, C. D. Morrow, J. E. Reardon, and P. A. Furman. 1996. Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5′-triphosphate. J. Biol. Chem. 271:13656-13662.
46. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102: 1769-1775.